(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 18.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Biocryst Pharmaceuticals's revenue in 2025 is $450,712,000.On average, 4 Wall Street analysts forecast BCRX's revenue for 2025 to be $118,107,755,624, with the lowest BCRX revenue forecast at $117,266,273,624, and the highest BCRX revenue forecast at $119,128,107,402. On average, 4 Wall Street analysts forecast BCRX's revenue for 2026 to be $136,507,312,265, with the lowest BCRX revenue forecast at $131,450,479,781, and the highest BCRX revenue forecast at $140,460,835,844.
In 2027, BCRX is forecast to generate $157,824,368,706 in revenue, with the lowest revenue forecast at $148,852,670,247 and the highest revenue forecast at $166,910,995,175.